A BILL 
To amend title XVIII of the Social Security Act to provide 
for the negotiation of lower covered part D drug prices 
on behalf of Medicare beneficiaries and the establishment 
and application of a formulary by the Secretary of 
Health and Human Services under Medicare part D, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
22:55 Jan 24, 2019
H448
2 
•HR 448 IH
SECTION 1. SHORT TITLE. 
1
This Act may be cited as the ‘‘Medicare Drug Price 
2
Negotiation Act’’. 
3
SEC. 2. NEGOTIATION OF LOWER COVERED PART D DRUG 
4
PRICES ON BEHALF OF MEDICARE BENE-
5
FICIARIES; ESTABLISHMENT AND APPLICA-
6
TION OF FORMULARY BY THE SECRETARY OF 
7
HEALTH 
AND 
HUMAN 
SERVICES 
UNDER 
8
MEDICARE PART D. 
9
(a) IN GENERAL.—Section 1860D–11 of the Social 
10
Security Act (42 U.S.C. 1395w–111) is amended by strik-
11
ing subsection (i) (relating to noninterference) and insert-
12
ing the following: 
13
‘‘(i) NEGOTIATION OF LOWER DRUG PRICES; ESTAB-
14
LISHMENT AND APPLICATION OF FORMULARY.— 
15
‘‘(1) NEGOTIATION.— 
16
‘‘(A) IN GENERAL.—Notwithstanding any 
17
other provision of law, subject to subparagraph 
18
(B), the Secretary shall, with respect to an ap-
19
plicable period (as defined in subparagraph 
20
(H))— 
21
‘‘(i) during the negotiation year (as 
22
defined in such subparagraph) for such pe-
23
riod, negotiate with pharmaceutical manu-
24
facturers the prices (including discounts, 
25
rebates, and all other price concessions) 
26
22:55 Jan 24, 2019
H448
3 
•HR 448 IH
that may be charged to PDP sponsors and 
1
MA organizations for applicable covered 
2
part D drugs (as defined in such subpara-
3
graph) furnished to enrollees during such 
4
period; and 
5
‘‘(ii) complete such negotiations not 
6
less than 30 days before the first day of 
7
the application review process for the first 
8
plan year during the applicable period for 
9
new contracts or expanding existing con-
10
tracts with PDP sponsors and MA organi-
11
zations to offer prescription drug plans or 
12
MA–PD plans, respectively. 
13
‘‘(B) USE OF FALLBACK IF NEGOTIATIONS 
14
FAIL.— 
15
‘‘(i) IN GENERAL.—If, after negotia-
16
tions under subparagraph (A) with respect 
17
to an applicable period, the Secretary is 
18
not successful in obtaining an appropriate 
19
price for applicable covered part D drugs 
20
in accordance with clause (ii), the price 
21
that may be charged to PDP sponsors and 
22
MA organizations for applicable covered 
23
part D drugs furnished to enrollees during 
24
22:55 Jan 24, 2019
H448
4 
•HR 448 IH
such period shall be the lowest of the fol-
1
lowing: 
2
‘‘(I) The contract price applied 
3
pursuant to section 8126 of title 38, 
4
United States Code, for such drug for 
5
the contract year (as defined in such 
6
section 8126). 
7
‘‘(II) The average of the prices 
8
available, during the most recent 12- 
9
month period for which data is avail-
10
able from the manufacturer to any 
11
wholesaler, retailer, provider, health 
12
maintenance organization, nonprofit 
13
entity, or governmental entity in Can-
14
ada, the United Kingdom, Germany, 
15
France, and Japan. 
16
‘‘(III) The best price determined 
17
under section 1927(c)(1)(C) for such 
18
drug for the most recent rebate period 
19
(as defined in section 1927(k)(8)) ap-
20
plicable to such first plan year of the 
21
applicable period. 
22
‘‘(ii) GUIDANCE.—Not later than 6 
23
months before the Secretary begins nego-
24
tiations under subparagraph (A) with re-
25
22:55 Jan 24, 2019
H448
5 
•HR 448 IH
spect to the first applicable period, the 
1
Secretary shall issue guidance on criteria 
2
to be considered for purposes of deter-
3
mining under clause (i) whether or not the 
4
Secretary is successful in obtaining an ap-
5
propriate price for an applicable covered 
6
part D drug. Such criteria shall include at 
7
least the following: 
8
‘‘(I) The comparative clinical ef-
9
fectiveness and cost effectiveness, if 
10
available, of such covered part D 
11
drug. 
12
‘‘(II) The budgetary impact of 
13
providing coverage under this part for 
14
such covered part D drug. 
15
‘‘(III) The number of similarly 
16
effective drug or alternative treatment 
17
regimens for each approved use of 
18
such covered part D drug. 
19
‘‘(IV) Associated unmet need or 
20
severity of illness. 
21
‘‘(C) IDENTIFICATION
OF
APPLICABLE 
22
COVERED PART D DRUGS.— 
23
‘‘(i) IN
GENERAL.—The Secretary 
24
shall, for each applicable period, in accord-
25
22:55 Jan 24, 2019
H448
6 
•HR 448 IH
ance with the subsequent clauses of this 
1
subparagraph, and pursuant to rule-
2
making, identify applicable covered part D 
3
drugs for which negotiations under sub-
4
paragraph (A) shall be conducted during 
5
the negotiation year for such period. In 
6
this paragraph, all such covered part D 
7
drugs so identified for an applicable period 
8
are collectively referred to as applicable 
9
covered part D drugs with respect to such 
10
period. 
11
‘‘(ii) IDENTIFICATION OF PRIORITIZED 
12
DRUGS.—In carrying out clause (i), except 
13
as provided under clause (iii), the Sec-
14
retary may not identify a covered part D 
15
drug that is not a drug prioritized pursu-
16
ant to subparagraph (D) as an applicable 
17
covered part D drug until all covered part 
18
D drugs that are so prioritized have been 
19
identified as an applicable covered part D 
20
drug for the applicable period or for a pre-
21
vious applicable period for which the nego-
22
tiated price of such drug has not expired. 
23
‘‘(iii) DRUG
INCLUSIONS
FOR
PRICE 
24
RENEGOTIATIONS.—In the case of a cov-
25
22:55 Jan 24, 2019
H448
7 
•HR 448 IH
ered part D drug that is identified as an 
1
applicable covered part D drug for an ap-
2
plicable period, such covered part D drug 
3
shall be identified as an applicable covered 
4
part D drug for each subsequent third ne-
5
gotiation year. 
6
‘‘(iv) REASONABLE
NOTIFICATION.— 
7
The Secretary shall carry out this subpara-
8
graph in such manner as to provide for 
9
public notification of applicable covered 
10
part D drugs for the applicable period 
11
within a reasonable period before the be-
12
ginning of the negotiation year for such 
13
period. 
14
‘‘(D) PRIORITIZATION
OF
CERTAIN
COV-
15
ERED PART D DRUGS.—For purposes of sub-
16
paragraph (C)(ii), the Secretary shall prioritize 
17
covered part D drugs— 
18
‘‘(i) that are among— 
19
‘‘(I) the 40 covered part D drugs 
20
that are utilized by at least 1,000 
21
Medicare part D beneficiaries and 
22
with respect to which there were the 
23
highest total expenditures under this 
24
22:55 Jan 24, 2019
H448
8 
•HR 448 IH
part during the most recent 12-month 
1
period for which data is available; 
2
‘‘(II) the 40 covered part D 
3
drugs that are utilized by at least 
4
1,000 Medicare part D beneficiaries 
5
with respect to whom the total annual 
6
spending per such a beneficiary under 
7
this part for coverage of such a drug 
8
is at least $10,000; or 
9
‘‘(III) the 20 covered part D 
10
drugs that are utilized by at least 
11
1,000 Medicare part D beneficiaries 
12
and with respect to which there are 
13
unit cost increases at or above the 
14
95th percentile of overall covered part 
15
D drug unit cost increases during the 
16
most recent 12-month period prior to 
17
the beginning of such negotiation year 
18
for which data is available; 
19
‘‘(ii) with respect to which the cost of 
20
such a drug to the part D eligible indi-
21
vidual involved would exceed the annual 
22
out-of-pocket threshold applicable under 
23
section 1860D–2(b)(4)(B) for such nego-
24
tiation year, if the drug were prescribed to 
25
22:55 Jan 24, 2019
H448
9 
•HR 448 IH
the individual for the period of the year or 
1
with respect to which a single treatment 
2
regimen is priced above such annual out- 
3
of-pocket threshold applicable under such 
4
section 1860D–2(b)(4)(B) for the year; or 
5
‘‘(iii) that are single-source drugs or 
6
biologicals 
(as 
defined 
in 
section 
7
1847A(c)(6)(D)) and that satisfy at least 
8
one other criterion described in a previous 
9
clause of this subparagraph. 
10
‘‘(E) ANNUAL
REPORT
TO
CONGRESS.— 
11
Not later than 30 days after the date on which 
12
the Secretary completes negotiations under this 
13
paragraph for the first negotiation year and 
14
each year thereafter, the Secretary shall submit 
15
to Congress and make available to the public a 
16
report describing the negotiations during the 
17
preceding negotiation year, including— 
18
‘‘(i) the number of applicable covered 
19
part D drug prices negotiated; 
20
‘‘(ii) 
the 
magnitude 
of 
savings 
21
achieved as a result of such negotiations; 
22
‘‘(iii) the number of times price nego-
23
tiations failed (based on the criteria in-
24
cluded in the guidance issued pursuant to 
25
22:55 Jan 24, 2019
H448
10 
•HR 448 IH
clause (ii) of subparagraph (B)) and re-
1
sulted in the use of fallback prices under 
2
clause (i) of such subparagraph, and the 
3
rationale for any such decisions; 
4
‘‘(iv) the progress made toward nego-
5
tiating the prices of covered part D drugs 
6
that are prioritized under subparagraph 
7
(D); and 
8
‘‘(v) the barriers, if any, to achieving 
9
savings through negotiations. 
10
‘‘(F) GAO REPORT.—Not later than De-
11
cember 31, 2024, the Comptroller General of 
12
the United States shall submit to Congress a 
13
report on the negotiations conducted by the 
14
Secretary under this paragraph, including a de-
15
scription and analysis of— 
16
‘‘(i) the extent to which such price ne-
17
gotiations are achieving lower prices for 
18
covered part D drugs for enrollees; 
19
‘‘(ii) the parties benefitting from such 
20
lower prices, such as enrollees, the Federal 
21
government, 
States, 
prescription 
drug 
22
plans and MA–PD plans, or other entities; 
23
‘‘(iii) how such price negotiations are 
24
affecting— 
25
22:55 Jan 24, 2019
H448
11 
•HR 448 IH
‘‘(I) the list price of covered part 
1
D drugs; and 
2
‘‘(II) drug prices in the private 
3
market; and 
4
‘‘(iv) recommendations for improving 
5
price negotiations, if applicable. 
6
‘‘(G) DEFINITIONS.—For purposes of this 
7
paragraph: 
8
‘‘(i) APPLICABLE
COVERED
PART
D 
9
DRUGS.—The term ‘applicable covered part 
10
D drugs’ means, for an applicable period, 
11
covered part D drugs identified by the Sec-
12
retary under subparagraph (C) for such 
13
period. 
14
‘‘(ii) APPLICABLE PERIOD.—The term 
15
‘applicable period’ means, with respect to a 
16
negotiation year and applicable covered 
17
part D drugs, the 3-plan year period be-
18
ginning with the first plan year beginning 
19
after the negotiation year for such covered 
20
part D drugs. 
21
‘‘(iii) NEGOTIATION YEAR.—The term 
22
‘negotiation year’ means, with respect to 
23
an applicable period, a plan year, begin-
24
22:55 Jan 24, 2019
H448
12 
•HR 448 IH
ning with 2020, prior to the first plan year 
1
of the applicable period. 
2
‘‘(2) ESTABLISHMENT
AND
APPLICATION
OF 
3
FORMULARY BY THE SECRETARY OR CHANGES IN 
4
FORMULARIES TO BE REQUIRED BY SECRETARY.— 
5
‘‘(A) IN GENERAL.—The Secretary shall, 
6
for plan years beginning with plan year 2020— 
7
‘‘(i) subject to subparagraphs (B) and 
8
(C), establish and apply a formulary for 
9
required use by sponsors of prescription 
10
drug plans and organizations offering MA– 
11
PD plans under this part; or 
12
‘‘(ii) require changes, as necessary, in 
13
the covered part D drugs included on 
14
formularies of PDP sponsors of prescrip-
15
tion drug plans (including changes, as nec-
16
essary, in the preferred or tiered cost-shar-
17
ing status of such a drug) to take into ac-
18
count negotiations carried out by the Sec-
19
retary pursuant to paragraph (1), regard-
20
less of whether such a covered part D drug 
21
is the subject of such negotiations. 
22
‘‘(B) REQUIRED INCLUSION OF DRUGS IN 
23
ALL THERAPEUTIC CATEGORIES.—A formulary 
24
established and applied under subparagraph 
25
22:55 Jan 24, 2019
H448
13 
•HR 448 IH
(A)(i) shall include at least two covered part D 
1
drugs in each category and class of covered part 
2
D 
drugs 
as 
described 
in 
section 
3
423.120(b)(2)(i) of title 42, Code of Federal 
4
Regulations (as in effect on January 1, 2017). 
5
‘‘(C) APPLICATION OF DEVELOPMENT AND 
6
REVISION REQUIREMENTS AND REQUIRED IN-
7
CLUSION
OF
ALL
DRUGS
IN
CERTAIN
CAT-
8
EGORIES AND CLASSES.—The requirements de-
9
scribed in subparagraphs (A) and (B) of section 
10
1860D–4(b)(3) (relating to development and re-
11
vision requirements of the formulary) and sub-
12
paragraph (G) of such section (relating to re-
13
quired inclusion of all drugs in certain cat-
14
egories and classes) shall apply to a formulary 
15
established and applied under subparagraph 
16
(A)(i) of this paragraph. 
17
‘‘(3) PLAN FLEXIBILITY TO NEGOTIATE GREAT-
18
ER DISCOUNTS.—Nothing in this subsection shall be 
19
construed as preventing the sponsor of a prescrip-
20
tion drug plan, or an organization offering an MA– 
21
PD plan, from obtaining a discount or reduction of 
22
the price for a covered part D drug below the price 
23
negotiated under paragraph (1), if applicable, in-
24
22:55 Jan 24, 2019
H448
14 
•HR 448 IH
cluding through the use of preferred or tiered cost- 
1
sharing status. 
2
‘‘(4) ENSURING
BENEFICIARY
ACCESS
TO 
3
NEEDED DRUGS.—Beginning with plan year 2020, 
4
each PDP sponsor of a prescription drug plan and 
5
organization offering an MA–PD plan shall have in 
6
place a process under which an enrollee in the plan 
7
may request coverage under the plan for a covered 
8
part D drug that is not on the formulary, or is sub-
9
ject to utilization management controls, such as 
10
tiered pricing, prior authorization, or step therapy.’’. 
11
(b) CONFORMING AMENDMENTS.— 
12
(1) IN GENERAL.—Section 1860D–4 of the So-
13
cial Security Act (42 U.S.C. 1395w–104) is amend-
14
ed— 
15
(A) in subsection (b)(3), in the matter pre-
16
ceding subparagraph (A), by striking ‘‘If a 
17
PDP’’ and inserting ‘‘Subject to section 
18
1860D–11(i)(2), if a PDP’’; 
19
(B) in subsection (g)— 
20
(i) in paragraph (1), by inserting be-
21
fore the period at the end the following: ‘‘, 
22
except that the PDP sponsor of a prescrip-
23
tion drug plan shall treat the presentation 
24
of a prescription to a participating phar-
25
22:55 Jan 24, 2019
H448
15 
•HR 448 IH
macy, which is transmitted to the plan by 
1
the pharmacy, as a request for a coverage 
2
determination (including with respect to 
3
prior authorization, step therapy, or quan-
4
tity limits) and, in applying such para-
5
graphs of section 1852(g), the response to 
6
such transmittal shall be treated as a de-
7
termination by the sponsor’’; and 
8
(ii) in paragraph (2), in the first sen-
9
tence, by inserting ‘‘(or a participating 
10
pharmacy, on behalf of such individual, 
11
through transmission of a prescription as 
12
described in paragraph (1))’’ after ‘‘a part 
13
D eligible individual who is enrolled in the 
14
plan’’; and 
15
(C) in subsection (h)— 
16
(i) in paragraph (1), in the second 
17
sentence, by inserting ‘‘(or a participating 
18
pharmacy, on behalf of such individual)’’ 
19
after ‘‘the part D eligible individual’’; and 
20
(ii) in paragraph (2), by inserting 
21
‘‘(or a participating pharmacy, on behalf of 
22
such individual)’’ after ‘‘A part D eligible 
23
individual who is enrolled in a prescription 
24
drug plan offered by a PDP sponsor’’. 
25
22:55 Jan 24, 2019
H448
16 
•HR 448 IH
(2) EFFECTIVE DATE.—The amendments made 
1
by subparagraphs (B) and (C) of paragraph (1) 
2
shall apply to plans years beginning on or after Jan-
3
uary 1, 2020. 
4
SEC. 3. REQUIRING DRUG MANUFACTURERS TO PROVIDE 
5
DRUG REBATES FOR DRUGS DISPENSED TO 
6
LOW-INCOME INDIVIDUALS. 
7
(a) IN GENERAL.—Section 1860D–2 of the Social 
8
Security Act (42 U.S.C. 1395w–102) is amended— 
9
(1) in subsection (e)(1), in the matter preceding 
10
subparagraph (A), by inserting ‘‘and subsection (f)’’ 
11
after ‘‘this subsection’’; and 
12
(2) by adding at the end the following new sub-
13
section: 
14
‘‘(f) PRESCRIPTION DRUG REBATE AGREEMENT FOR 
15
REBATE ELIGIBLE INDIVIDUALS.— 
16
‘‘(1) REQUIREMENT.— 
17
‘‘(A) IN GENERAL.—For plan years begin-
18
ning on or after January 1, 2020, in this part, 
19
the term ‘covered part D drug’ does not include 
20
any drug or biological product that is manufac-
21
tured by a manufacturer that has not entered 
22
into and have in effect a rebate agreement de-
23
scribed in paragraph (2). 
24
22:55 Jan 24, 2019
H448
17 
•HR 448 IH
‘‘(B) 2020 PLAN YEAR REQUIREMENT.— 
1
Any drug or biological product manufactured by 
2
a manufacturer that declines to enter into a re-
3
bate agreement described in paragraph (2) for 
4
the period beginning on January 1, 2020, and 
5
ending on December 31, 2020, shall not be in-
6
cluded as a ‘covered part D drug’ for the subse-
7
quent plan year. 
8
‘‘(2) REBATE
AGREEMENT.—A rebate agree-
9
ment under this subsection shall require the manu-
10
facturer to provide to the Secretary a rebate for 
11
each rebate period (as defined in paragraph (6)(B)) 
12
ending after December 31, 2019, in the amount 
13
specified in paragraph (3) for any covered part D 
14
drug of the manufacturer dispensed after December 
15
31, 2019, to any rebate eligible individual (as de-
16
fined in paragraph (6)(A)) for which payment was 
17
made by a PDP sponsor or MA organization under 
18
this part for such period, including payments passed 
19
through the low-income and reinsurance subsidies 
20
under sections 1860D–14 and 1860D–15(b), respec-
21
tively. Such rebate shall be paid by the manufac-
22
turer to the Secretary not later than 30 days after 
23
the date of receipt of the information described in 
24
section 1860D–12(b)(8), including as such section is 
25
22:55 Jan 24, 2019
H448
18 
•HR 448 IH
applied under section 1857(f)(3), or 30 days after 
1
the receipt of information under subparagraph (D) 
2
of paragraph (3), as determined by the Secretary. 
3
Insofar as not inconsistent with this subsection, the 
4
Secretary shall establish terms and conditions of 
5
such agreement relating to compliance, penalties, 
6
and program evaluations, investigations, and audits 
7
that are similar to the terms and conditions for re-
8
bate agreements under paragraphs (3) and (4) of 
9
section 1927(b). 
10
‘‘(3) REBATE FOR REBATE ELIGIBLE MEDICARE 
11
DRUG PLAN ENROLLEES.— 
12
‘‘(A) IN GENERAL.—The amount of the re-
13
bate specified under this paragraph for a manu-
14
facturer for a rebate period, with respect to 
15
each dosage form and strength of any covered 
16
part D drug provided by such manufacturer 
17
and dispensed to a rebate eligible individual, 
18
shall be equal to the product of— 
19
‘‘(i) the total number of units of such 
20
dosage form and strength of the drug so 
21
provided and dispensed for which payment 
22
was made by a PDP sponsor or an MA or-
23
ganization under this part for the rebate 
24
period, including payments passed through 
25
22:55 Jan 24, 2019
H448
19 
•HR 448 IH
the low-income and reinsurance subsidies 
1
under sections 1860D–14 and 1860D– 
2
15(b), respectively; and 
3
‘‘(ii) the amount (if any) by which— 
4
‘‘(I) the Medicaid rebate amount 
5
(as defined in subparagraph (B)) for 
6
such form, strength, and period, ex-
7
ceeds 
8
‘‘(II) the average Medicare drug 
9
program rebate eligible rebate amount 
10
(as defined in subparagraph (C)) for 
11
such form, strength, and period. 
12
‘‘(B) MEDICAID
REBATE
AMOUNT.—For 
13
purposes of this paragraph, the term ‘Medicaid 
14
rebate amount’ means, with respect to each 
15
dosage form and strength of a covered part D 
16
drug provided by the manufacturer for a rebate 
17
period— 
18
‘‘(i) in the case of a single source 
19
drug or an innovator multiple source drug, 
20
the 
amount 
specified 
in 
paragraph 
21
(1)(A)(ii)(II) or (2)(C) of section 1927(c) 
22
plus the amount, if any, specified in sub-
23
paragraph (A)(ii) of paragraph (2) of such 
24
22:55 Jan 24, 2019
H448
20 
•HR 448 IH
section, for such form, strength, and pe-
1
riod; or 
2
‘‘(ii) in the case of any other covered 
3
outpatient drug, the amount specified in 
4
paragraph (3)(A)(i) of such section for 
5
such form, strength, and period. 
6
‘‘(C) AVERAGE MEDICARE DRUG PROGRAM 
7
REBATE ELIGIBLE REBATE AMOUNT.—For pur-
8
poses of this subsection, the term ‘average 
9
Medicare drug program rebate eligible rebate 
10
amount’ means, with respect to each dosage 
11
form and strength of a covered part D drug 
12
provided by a manufacturer for a rebate period, 
13
the sum, for all PDP sponsors under part D 
14
and MA organizations administering an MA– 
15
PD plan under part C, of— 
16
‘‘(i) the product, for each such spon-
17
sor or organization, of— 
18
‘‘(I) the sum of all rebates, dis-
19
counts, or other price concessions (not 
20
taking into account any rebate pro-
21
vided under paragraph (2) or any dis-
22
counts under the program under sec-
23
tion 1860D–14A) for such dosage 
24
form and strength of the drug dis-
25
22:55 Jan 24, 2019
H448
21 
•HR 448 IH
pensed, calculated on a per-unit basis, 
1
but only to the extent that any such 
2
rebate, discount, or other price con-
3
cession applies equally to drugs dis-
4
pensed to rebate eligible Medicare 
5
drug plan enrollees and drugs dis-
6
pensed to PDP and MA–PD enrollees 
7
who are not rebate eligible individuals; 
8
and 
9
‘‘(II) the number of the units of 
10
such dosage and strength of the drug 
11
dispensed during the rebate period to 
12
rebate eligible individuals enrolled in 
13
the prescription drug plans adminis-
14
tered by the PDP sponsor or the MA– 
15
PD plans administered by the MA or-
16
ganization; divided by 
17
‘‘(ii) the total number of units of such 
18
dosage and strength of the drug dispensed 
19
during the rebate period to rebate eligible 
20
individuals enrolled in all prescription drug 
21
plans administered by PDP sponsors and 
22
all MA–PD plans administered by MA or-
23
ganizations. 
24
22:55 Jan 24, 2019
H448
22 
•HR 448 IH
‘‘(D) USE OF ESTIMATES.—The Secretary 
1
may establish a methodology for estimating the 
2
average Medicare drug program rebate eligible 
3
rebate amounts for each rebate period based on 
4
bid and utilization information under this part 
5
and may use these estimates as the basis for 
6
determining the rebates under this section. If 
7
the Secretary elects to estimate the average 
8
Medicare drug program rebate eligible rebate 
9
amounts, the Secretary shall establish a rec-
10
onciliation process for adjusting manufacturer 
11
rebate payments not later than 3 months after 
12
the date that manufacturers receive the infor-
13
mation 
collected 
under 
section 
1860D– 
14
12(b)(8)(B). 
15
‘‘(4) LENGTH OF AGREEMENT.—The provisions 
16
of paragraph (4) of section 1927(b) (other than 
17
clauses (iv) and (v) of subparagraph (B)) shall apply 
18
to rebate agreements under this subsection in the 
19
same manner as such paragraph applies to a rebate 
20
agreement under such section. 
21
‘‘(5) OTHER
TERMS
AND
CONDITIONS.—The 
22
Secretary shall establish other terms and conditions 
23
of the rebate agreement under this subsection, in-
24
22:55 Jan 24, 2019
H448
23 
•HR 448 IH
cluding terms and conditions related to compliance, 
1
that are consistent with this subsection. 
2
‘‘(6) DEFINITIONS.—In this subsection and sec-
3
tion 1860D–12(b)(8): 
4
‘‘(A) REBATE ELIGIBLE INDIVIDUAL.—The 
5
term ‘rebate eligible individual’ means— 
6
‘‘(i) a subsidy eligible individual (as 
7
defined in section 1860D–14(a)(3)(A)); 
8
‘‘(ii) a Medicaid beneficiary treated as 
9
a subsidy eligible individual under clause 
10
(v) of section 1860D–14(a)(3)(B); and 
11
‘‘(iii) any part D eligible individual 
12
not described in clause (i) or (ii) who is de-
13
termined for purposes of the State plan 
14
under title XIX to be eligible for medical 
15
assistance under clause (i), (iii), or (iv) of 
16
section 1902(a)(10)(E). 
17
‘‘(B) REBATE PERIOD.—The term ‘rebate 
18
period’ has the meaning given such term in sec-
19
tion 1927(k)(8).’’. 
20
(b) REPORTING REQUIREMENT
FOR
THE DETER-
21
MINATION AND PAYMENT OF REBATES BY MANUFACTUR-
22
ERS RELATED TO REBATE FOR REBATE ELIGIBLE MEDI-
23
CARE DRUG PLAN ENROLLEES.— 
24
22:55 Jan 24, 2019
H448
24 
•HR 448 IH
(1) REQUIREMENTS FOR PDP SPONSORS.—Sec-
1
tion 1860D–12(b) of the Social Security Act (42 
2
U.S.C. 1395w–112(b)) is amended by adding at the 
3
end the following new paragraph: 
4
‘‘(8) REPORTING REQUIREMENT FOR THE DE-
5
TERMINATION AND PAYMENT OF REBATES BY MANU-
6
FACTURERS RELATED TO REBATE FOR REBATE ELI-
7
GIBLE MEDICARE DRUG PLAN ENROLLEES.— 
8
‘‘(A) IN GENERAL.—For purposes of the 
9
rebate under section 1860D–2(f) for contract 
10
years beginning on or after January 1, 2020, 
11
each contract entered into with a PDP sponsor 
12
under this part with respect to a prescription 
13
drug plan shall require that the sponsor comply 
14
with subparagraphs (B) and (C). 
15
‘‘(B) REPORT FORM AND CONTENTS.—Not 
16
later than a date specified by the Secretary, a 
17
PDP sponsor of a prescription drug plan under 
18
this part shall report to each manufacturer— 
19
‘‘(i) information (by National Drug 
20
Code number) on the total number of units 
21
of each dosage, form, and strength of each 
22
drug of such manufacturer dispensed to re-
23
bate eligible Medicare drug plan enrollees 
24
under any prescription drug plan operated 
25
22:55 Jan 24, 2019
H448
25 
•HR 448 IH
by the PDP sponsor during the rebate pe-
1
riod; 
2
‘‘(ii) information on the price dis-
3
counts, price concessions, and rebates for 
4
such drugs for such form, strength, and 
5
period; 
6
‘‘(iii) information on the extent to 
7
which such price discounts, price conces-
8
sions, and rebates apply equally to rebate 
9
eligible Medicare drug plan enrollees and 
10
PDP enrollees who are not rebate eligible 
11
Medicare drug plan enrollees; and 
12
‘‘(iv) any additional information that 
13
the Secretary determines is necessary to 
14
enable the Secretary to calculate the aver-
15
age Medicare drug program rebate eligible 
16
rebate amount (as defined in paragraph 
17
(3)(C) of such section), and to determine 
18
the amount of the rebate required under 
19
this section, for such form, strength, and 
20
period. 
21
Such report shall be in a form consistent with 
22
a standard reporting format established by the 
23
Secretary. 
24
22:55 Jan 24, 2019
H448
26 
•HR 448 IH
‘‘(C) SUBMISSION TO SECRETARY.—Each 
1
PDP sponsor shall promptly transmit a copy of 
2
the information reported under subparagraph 
3
(B) to the Secretary for the purpose of audit 
4
oversight and evaluation. 
5
‘‘(D) 
CONFIDENTIALITY
OF
INFORMA-
6
TION.—The provisions of subparagraph (D) of 
7
section 1927(b)(3), relating to confidentiality of 
8
information, shall apply to information reported 
9
by PDP sponsors under this paragraph in the 
10
same manner that such provisions apply to in-
11
formation disclosed by manufacturers or whole-
12
salers under such section, except— 
13
‘‘(i) that any reference to ‘this sec-
14
tion’ in clause (i) of such subparagraph 
15
shall be treated as being a reference to this 
16
section; 
17
‘‘(ii) the reference to the Director of 
18
the Congressional Budget Office in clause 
19
(iii) of such subparagraph shall be treated 
20
as including a reference to the Medicare 
21
Payment Advisory Commission; and 
22
‘‘(iii) clause (iv) of such subparagraph 
23
shall not apply. 
24
22:55 Jan 24, 2019
H448
27 
•HR 448 IH
‘‘(E) OVERSIGHT.—Information reported 
1
under this paragraph may be used by the In-
2
spector General of the Department of Health 
3
and Human Services for the statutorily author-
4
ized purposes of audit, investigation, and eval-
5
uations. 
6
‘‘(F) PENALTIES
FOR
FAILURE
TO
PRO-
7
VIDE TIMELY INFORMATION AND PROVISION OF 
8
FALSE INFORMATION.—In the case of a PDP 
9
sponsor— 
10
‘‘(i) that fails to provide information 
11
required under subparagraph (B) on a 
12
timely basis, the sponsor is subject to a 
13
civil money penalty in the amount of 
14
$10,000 for each day in which such infor-
15
mation has not been provided; or 
16
‘‘(ii) that knowingly (as defined in 
17
section 1128A(i)) provides false informa-
18
tion under such subparagraph, the sponsor 
19
is subject to a civil money penalty in an 
20
amount not to exceed $100,000 for each 
21
item of false information. 
22
Such civil money penalties are in addition to 
23
other penalties as may be prescribed by law. 
24
The provisions of section 1128A (other than 
25
22:55 Jan 24, 2019
H448
28 
•HR 448 IH
subsections (a) and (b)) shall apply to a civil 
1
money penalty under this subparagraph in the 
2
same manner as such provisions apply to a pen-
3
alty or proceeding under section 1128A(a).’’. 
4
(2) APPLICATION TO MA ORGANIZATIONS.—Sec-
5
tion 1857(f)(3) of the Social Security Act (42 
6
U.S.C. 1395w–27(f)(3)) is amended by adding at 
7
the end the following: 
8
‘‘(E) REPORTING REQUIREMENT RELATED 
9
TO REBATE FOR REBATE ELIGIBLE MEDICARE 
10
DRUG
PLAN
ENROLLEES.—Section 1860D– 
11
12(b)(8).’’. 
12
(c) DEPOSIT OF REBATES INTO MEDICARE PRE-
13
SCRIPTION DRUG ACCOUNT.—Section 1860D–16(c) of the 
14
Social Security Act (42 U.S.C. 1395w–116(c)) is amended 
15
by adding at the end the following new paragraph: 
16
‘‘(6) REBATE FOR REBATE ELIGIBLE MEDICARE 
17
DRUG PLAN ENROLLEES.—Amounts paid under a re-
18
bate agreement under section 1860D–2(f) shall be 
19
deposited into the Account.’’. 
20
(d) EXCLUSION FROM DETERMINATION
OF BEST 
21
PRICE
AND AVERAGE MANUFACTURER PRICE UNDER 
22
MEDICAID.— 
23
(1) EXCLUSION FROM BEST PRICE DETERMINA-
24
TION.—Section 1927(c)(1)(C)(ii)(I) of the Social Se-
25
22:55 Jan 24, 2019
H448
29 
•HR 448 IH
curity Act (42 U.S.C. 1396r–8(c)(1)(C)(ii)(I)) is 
1
amended by inserting ‘‘and amounts paid under a 
2
rebate agreement under section 1860D–2(f)’’ after 
3
‘‘this section’’. 
4
(2) EXCLUSION
FROM
AVERAGE
MANUFAC-
5
TURER
PRICE
DETERMINATION.—Section 
6
1927(k)(1)(B)(i) of the Social Security Act (42 
7
U.S.C. 1396r–8(k)(1)(B)(i)) is amended— 
8
(A) in subclause (IV), by striking ‘‘and’’ 
9
after the semicolon; 
10
(B) in subclause (V), by striking the period 
11
at the end and inserting ‘‘; and’’; and 
12
(C) by adding at the end the following: 
13
‘‘(VI) amounts paid under a re-
14
bate agreement under section 1860D– 
15
2(f).’’. 
16
Æ 
22:55 Jan 24, 2019
H448
